07:00 , Oct 22, 2012 |  BioCentury  |  Strategy

NPS's niche save

After its big bet on an osteoporosis candidate failed in 2006, NPS Pharmaceuticals Inc. slimmed down and refocused on developing its pipeline for Orphan diseases. The strategy looks to be paying off after last month's...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Arius board of directors update

Arius Research Inc. (TSX:ARI), Toronto, Canada   Business: Cancer   Appointed: Graham Strachan, former president and CEO of Allelix Biopharmaceuticals Inc.   Retired: William Bodenhamer  ...
07:00 , Aug 27, 2007 |  BioCentury  |  Tools & Techniques

Harnessing sodium channels

Sodium channels are large voltage-gated transmembrane proteins that play an important role in many physiological processes by regulating the entry and exit of charged ions. Because of this role as ion gatekeepers, they have proven...
07:00 , May 6, 2002 |  BC Week In Review  |  Company News

Xenon Genetics Inc. management update

Xenon Genetics Inc. , Vancouver, B.C.   Business: Pharmacogenetics, Cardiovascular   Hired: Rajender Kamboj as VP of drug discovery, formerly VP and CSO at NPS Pharmaceuticals Inc. 's Allelix Biopharmaceuticals Inc. subsidiary  ...
08:00 , Mar 25, 2002 |  BC Week In Review  |  Company News

GB Therapeutics board of directors update

GB Therapeutics, Kingston, Ontario   Business: Cardiovascular, Neurological   Appointed: John Molloy, president and CEO of Parteq Innovations, as chairman; Ian Anderson, president and CEO; James Reynolds, VP of biological sciences; Jean-Paul St. Pierre, physician;...
07:00 , Jun 18, 2001 |  BC Week In Review  |  Company News

Vivus board of directors update

Vivus Inc. (VVUS), Mountain View, Calif.   Business: Urological, Reproductive   Appointed: Graham Strachan, former president and CEO of Allelix Biopharmaceuticals Inc.  ...
07:00 , May 7, 2001 |  BC Week In Review  |  Company News

Lorus board of directors update

Lorus Therapeutics Inc. (TSE:LOR; LORFF), Toronto, Ontario   Business: Cancer   Appointed: Alan Steigrod, former EVP of sales & marketing at Glaxo Inc.; and Graham Strachan, former president and CEO of Allelix Biopharmaceuticals Inc.  ...
07:00 , Oct 23, 2000 |  BC Week In Review  |  Company News

Labopharm management update

Labopharm Inc. (TSE:DDS), Montreal, Quebec   Business: Drug delivery   Promoted: Vincent Lenaerts to CSO while remaining VP of R&D   Hired: Allan Mandelzys as VP of business development, formerly director of business development at...
07:00 , Sep 5, 2000 |  BC Week In Review  |  Company News

NPS, Forest Laboratories deal

NPSP's NPS Allelix Corp. subsidiary (Toronto, Ontario) granted FRX exclusive worldwide development and marketing rights to its ALX-0646 selective serotonin agonist to treat migraine. The product has completed Phase I testing outside the U.S. Packard...
07:00 , Aug 7, 2000 |  BC Week In Review  |  Company News

Icagen, NPS Allelix, University of California deal

ICAgen received from NPS Allelix, a subsidiary of NPS Pharmaceuticals Inc. (NPSP; TSE:NX, Salt Lake City, Utah), an exclusive license to sodium channels expressed in peripheral nerve cells that regulate cellular excitability in pain pathways....